Browse the evidence

Metabolic dysfunction-associated steatotic liver disease (MASLD) is very common in individuals with type 2 diabetes.

Healthcare providers should be aware of the high prevalence of MASLD in their diabetic patients.

THDBH120 is a novel long-acting dual GIPR/GLP-1R agonist that has superior weight loss and metabolic improvement effects in rodents and mammals.

THDBH120 may be a promising treatment option for obesity and metabolic disorders.

Perturbation of gut-brain-pancreas communication contributes to metabolic disorders such as obesity and type 2 diabetes.

Recognizing these perturbations can guide therapeutic approaches for metabolic disorders.

The presence of metabolic abnormalities doubles event rates associated with obesity, with risk increasing with the number of metabolic abnormalities present.

Practitioners should consider the presence of metabolic abnormalities when assessing the risks of obesity in patients.

Metabolic parameters such as glycaemic, blood pressure, and lipid levels return to baseline within approximately 12 months after discontinuation.

Healthcare providers should monitor metabolic parameters closely after discontinuation of GLP-1RA therapy.

At 2.5 years, White individuals experienced significantly greater body weight loss than Black individuals: −7.1% versus −4.9%.

Practitioners should be aware of racial differences in weight loss outcomes when prescribing GLP-1RA therapy.

White individuals had significantly larger reductions in estimated glomerular filtration rate, systolic blood pressure, and HbA1c compared to Black individuals.

Healthcare providers should consider these differences in clinical outcomes when treating patients with GLP-1RA.

Emerging single-anastomosis variants demonstrate promising efficacy and improved gastrointestinal profiles.

Clinicians should consider these emerging techniques for patients seeking bariatric surgery.

There was no significant effect of either whey or soy protein supplementation on lean body mass (LBM).

Practitioners should note that protein supplementation may not significantly increase lean body mass.

A high protein diet (PRO) had a limited benefit on metabolic flexibility compared to a control diet (CON).

While a high protein diet is beneficial, its impact on metabolic flexibility may not be significant for older adults.

Protein supplementation during aerobic training did not significantly enhance cardiorespiratory fitness compared with an isocaloric placebo.

Practitioners should consider that protein supplementation may not provide additional benefits for improving cardiorespiratory fitness in stroke patients undergoing aerobic training.

There was no significant relationship between body fat mass changes and daily protein intake.

Practitioners should note that increasing protein intake may not affect body fat loss in older women.

Insulin resistance in aging is a multisystem phenomenon reflecting declining metabolic adaptability rather than a simple glucose disorder.

Practitioners should consider insulin resistance as a complex, systemic issue in older patients, not just a glucose management problem.

A comprehensive redefinition of obesity in Asian Indians is needed beyond BMI criteria.

Practitioners should consider factors beyond BMI when diagnosing obesity in Asian Indians.

The refined framework aims to enhance precision in identifying obesity and its health risks.

Practitioners can use this framework to better assess obesity-related health risks.

Short term dietary trials are highly susceptible to bias due to physiological adaptation to major changes in nutrients.

Practitioners should be aware that results from short-term dietary trials may be influenced by the time it takes for physiological changes to occur.

Current research has focused more on muscle mass than on skeletal muscle lipid metabolism.

Researchers should shift focus to skeletal muscle lipid metabolism in future studies.

Nearly half of all patients listed for kidney transplant have obesity, which is associated with increased rates of perioperative complications and graft loss.

Healthcare providers should be aware of the high prevalence of obesity in kidney transplant candidates and its implications for surgery.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to increase from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050.

Health systems should prepare for a significant increase in MASLD cases.

Cases of metabolic dysfunction-associated steatohepatitis (MASH) are expected to rise from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050.

Increased awareness and management strategies for MASH are needed.

Liver-related mortality is estimated to increase from 30,500 deaths (1.0% of all-cause deaths in adults) in 2020 to 95,300 deaths (2.4%) in 2050.

Strategies to reduce liver-related mortality must be prioritized.

There is no clear evidence that GLP-1RAs and dual GLP-1/GIPRA enhance cardiorespiratory fitness (CRF).

Practitioners should be cautious in expecting improvements in CRF from these therapies.

The long-acting PYY analogs improved glucose metabolism in diabetic db/db mice.

Indicates potential for improved glucose control in diabetic patients.

Obesity is a chronic metabolic disorder that shares underlying pathophysiology with type 2 diabetes mellitus, cardiovascular disease, and diabetic cardiomyopathy.

Understanding the metabolic links can help in developing targeted interventions for obesity and related diseases.